Gimme Care vs Mochi Health
Two GLP-1 desks, one scoreboard. We put Gimme Care and Mochi Health head-to-head on the published Brief Score — the same six factors, scored the same way.
Mochi Health
The verdict
Mochi Health takes this head-to-head.
Mochi Health scores 81 to 78 on our six-factor Brief Score — A recognizable coaching-forward brand, but availability is capped at roughly 15 states.
That doesn't make Gimme Care a bad call — it's best for readers who want affordable compounded glp-1 with nationwide coverage and microdose options. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Gimme Care | Mochi Health | |
|---|---|---|
| Brief Score | 78/100 (C) | 81/100 (B−) |
| Semaglutide | From $130/mo (compounded) | $138/mo |
| Tirzepatide | From $163/mo (compounded) | $238/mo |
| Coverage | All 50 states | 15 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
| On the tracker | Newnew to the tracker, no prior reading | Stableprice stable |
Gimme Care: New to the tracker on 1 August 2026. The published line reads From $130/mo (compounded) at our first reading; there is no earlier reading of ours to compare it against yet.
Mochi Health: $138 sema / $238 tirz; footprint capped near 15 states.
● Not sold on either?
CoreAge Rx tops the whole ranking at 94/100.
The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.